NCT01915901 - PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Healthy

Interventions

DRUG

bismuth subsalicylate (Pepto-Bismol®)

524 mg bismuth subsalicylate twice a day (BID)

DRUG

matching placebo (bismuth subsalicylate)

placebo twice a day (BID)

DRUG

dimethyl fumarate (DMF)

dimethyl fumarate (DMF) twice a day (BID)

Trial Locations (3)

Research Site, Daytona Beach

Research Site, Madison

Research Site, Dallas